Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Medical Oncology
•
Renal Cell Carcinoma
How would you approach the use of bevacizumab in metastatic FH-deficient RCC/HLRCC that is c/b extensive IVC tumor thrombus and DVT/PE?
Related Questions
With increasing overlap between advanced clear cell and non-clear cell RCC management with IO+TKI therapy, are there subtypes of non-clear cell RCC for which you would not use this approach?
Would you offer adjuvant immunotherapy (pembrolizumab) for chromophobe RCC with R1 resection?
What adjuvant therapy, if any, is best for mucinous tubular and spindle cell carcinoma of the kidney?
Would the occurrence of obvious tumor rupture/spillage intraoperatively impact your decision for adjuvant systemic therapy after resection of either clear cell RCC or papillary RCC?
How would you approach a patient with metastatic renal cell carcinoma who developed a STEMI while on TKI (Lenvatinib) and immunotherapy combination?
Do you routinely continue patients on anti-PD(L)-1 beyond 2 years of treatment while on IO/TKI for metastatic ccRCC?
How do you manage hypoxia induced by belzutifan?
How often do you monitor for pancreatitis (check lipase/amylase) while on Axitinib?
What is your preferred regimen for a patient with clear cell RCC, progression after an IO+IO regimen, with a chronic non-healing wound?
Is there still a role for mTOR inhibitors in metastatic RCC in the immunotherapy/TKI era?
